Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines

Journal article


Publication Details

Author(s): Kittler J, Sommer J, Fischer A, Britting S, Karg M, Bock B, Atreya I, Heindl LM, Mackensen A, Bosch JJ
Journal: Oncotarget
Publication year: 2019
Volume: 10
Journal issue: 19
Pages range: 1812-1828
ISSN: 1949-2553


Abstract

Uveal melanoma is the most common primary malignancy of the eye in adults. Despite significant improvements in treatment of the primary tumor, to date none of these therapies prevent metastatic disease or improve overall survival. We are exploring immunotherapeutic options for metastatic uveal melanoma using MHC II uveal melanoma cell-based vaccines that target the activation of tumor-reactive CD4+ T cells. Previously, we showed that these uveal melanoma cell-based vaccines activate CD4+ T cells within total peripheral blood lymphocytes (PBMC). Since PBMC include professional antigen presenting cells, we now demonstrate that Mel202/ DR1/CD80 vaccine cells directly activate a diverse repertoire of purified, naïve CD4+ T cells. The activated CD4+ T cells proliferated, secreted high amounts of interferon gamma (IFNγ) and produced a heterogeneous profile of Th1, Th2 and Th17 cytokines. Analysis of the TCR-Vβ-repertoire showed that a polyclonal T cell response was induced, suggesting the capacity of vaccine-activated CD4+ T cells to target multiple tumor (neo)antigens. In addition, a subset of the responding CD4+ T cells expressed forkhead box protein P3 (FoxP3), indicating that although a regulatory component of the vaccine-activated CD4+ T cell response was induced, the anti-tumor vaccine response was not limited by these regulatory CD4+ T cells. Finally, Mel202/DR1/CD80 uveal melanoma vaccine cells expressed the intercellular adhesion molecule 1 (ICAM-1) that was pivotal for CD4+ T cell activation via lymphocyte function-associated antigen 1(LFA-1). In conclusion, MHC II uveal melanoma vaccines activate purified CD4+ T cells and may serve as a novel immunotherapy for uveal melanoma patients.


FAU Authors / FAU Editors

Britting, Sabine Dr.
Lehrstuhl für Innere Medizin (Geriatrie)
Karg, Margarete
Medizinische Klinik 5 - Hämatologie und Internistische Onkologie
Kittler, Julia
Medizinische Klinik 3 - Rheumatologie und Immunologie
Mackensen, Andreas Prof. Dr.
Lehrstuhl für Innere Medizin V


External institutions with authors

Universität Köln


How to cite

APA:
Kittler, J., Sommer, J., Fischer, A., Britting, S., Karg, M., Bock, B.,... Bosch, J.J. (2019). Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines. Oncotarget, 10(19), 1812-1828.

MLA:
Kittler, Julia, et al. "Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines." Oncotarget 10.19 (2019): 1812-1828.

BibTeX: 

Last updated on 2019-17-06 at 15:53